{
  "id": 11468061,
  "title": "Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s",
  "url": "https://urgent.news/2026/10/02/why-lilly-and-novo-are-betting-on-amylin-to-power-a-new-wave-of-11468061",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-02T15:20:29.000Z",
  "source": {
    "name": "CNBC World",
    "slug": "cnbc-world",
    "url": "https://www.cnbc.com/2026/10/02/lilly-novo-amylin-obesity-drugs.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Medical Xpress",
        "title": "Experimental obesity drug targets appetite through amylin, offering potential alternative to GLP-1 therapies",
        "url": "https://urgent.news/2026/09/30/experimental-obesity-drug-targets-appetite-through-amylin-offering",
        "published": "2026-09-30T17:00:11.000Z"
      },
      {
        "outlet": "CNBC",
        "title": "Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s",
        "url": "https://urgent.news/2026/10/02/why-lilly-and-novo-are-betting-on-amylin-to-power-a-new-wave-of",
        "published": "2026-10-02T15:20:29.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}